DexCom Financial Statements From 2010 to 2024
DXCM Stock | USD 134.00 2.48 1.89% |
Gross Profit 1.9 B | Profit Margin 0.1495 | Market Capitalization 50.7 B | Enterprise Value Revenue 14.4564 | Revenue 3.6 B |
DexCom Total Revenue |
|
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom main balance sheet or income statement drivers, such as Interest Expense of 15.5 M, Other Operating Expenses of 3.2 B or Operating Income of 627.6 M, as well as many exotic indicators such as Price To Sales Ratio of 23.64, Dividend Yield of 0.0206 or PTB Ratio of 24.31. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Select Account or Indicator |
DexCom Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DexCom Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DexCom Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DexCom Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DexCom Fundamental Market Drivers
Forward Price Earnings | 77.5194 | |
Cash And Short Term Investments | 2.7 B |
DexCom Upcoming Events
8th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
8th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
About DexCom Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include DexCom income statement, its balance sheet, and the statement of cash flows. DexCom investors use historical funamental indicators, such as DexCom's revenue or net income, to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DexCom Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DexCom. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Current Deferred Revenue | 18.4 M | 19.3 M | |
Total Revenue | 3.6 B | 3.8 B | |
Cost Of Revenue | 1.3 B | 1.4 B | |
Stock Based Compensation To Revenue | 0.04 | 0.04 | |
Sales General And Administrative To Revenue | 0.28 | 0.26 | |
Research And Ddevelopement To Revenue | 0.14 | 0.13 | |
Capex To Revenue | (0.07) | (0.07) | |
Revenue Per Share | 9.38 | 9.85 | |
Ebit Per Revenue | 0.17 | 0.17 |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving against DexCom Stock
0.81 | DH | Definitive Healthcare Financial Report 2nd of May 2024 | PairCorr |
0.79 | SIBN | Si Bone Financial Report 6th of May 2024 | PairCorr |
0.74 | SRDX | SurModics Earnings Call This Week | PairCorr |
0.73 | LNSR | LENSAR Inc | PairCorr |
0.72 | BWAY | Brainsway Financial Report 15th of May 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of DexCom Correlation against competitors. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.29 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.